Last updated
Biogen: Ma Activity
Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Source: GNW — Mergers & Acquisitions
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: Against a Talent Market Index of 111.1 (Hot) (up 5.2 month-on-month), Americas is at rising (+6.3pts) on signal share.
Biogen: 4 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.2% of MitchelLake's Americas signal flow; 4 tracked across 51 days.
MitchelLake in this thematic
Also at Biogen →
More signals across Biotech & Pharma
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Intelligence powered by Autonodal ↗